Radnostix Revenue Falls 22% to $2.57 Million; Asset Deal Awaits Approvals
Key Facts
Radnostix said on November 16 that revenue for the third quarter ended September 30, 2026, was $2.57 million, down 22% from $3.28 million in the same period of 2025. The company said in a statement that delays in cobalt contracts and weaker sales of calibration and reference products weighed on revenue, while growth in Theranostics products offset part of the decline. For the nine months ended September 30, the company reported revenue of $7.62 million, 25% below $10.17 million a year earlier. The results place the quarter in the context of a broader decline over the year, despite improved sales in one product line. The company also disclosed a higher quarterly loss and less cash than at the end of 2025.
The decline in cobalt sales was the main factor behind the weak quarter, with revenue from those products falling to $0.09 million, down 88% year over year. Radnostix said large contracts are awaiting amendments from the U.S. Nuclear Regulatory Commission to registered devices, and delivery of about $1.2 million in contracted cobalt sales was moved from the second half of 2026 to the first quarter of 2027. Revenue from calibration and reference products also fell to $0.74 million, down 23%, after a global disruption in cobalt-57 supplies curtailed sales. By contrast, Theranostics revenue rose to $1.71 million, up 15% year over year, as the number of customers increased, according to the company. That growth, however, did not offset the impact of weakness in other segments on total revenue.
The quarterly net loss widened to $842,242, compared with $203,601 in the third quarter of 2025. The company attributed the increase to weaker sales of cobalt, calibration products and medical devices, and higher operating expenses, partly offset by growth in Theranostics. Cash and cash equivalents stood at $711,288 on September 30, compared with $1,695,158 on December 31, 2025. Operations used $1,132,543 in cash during the first nine months of 2026, after providing $210,043 in the same period a year earlier. The figures show revenue declining alongside operating cash use during the period.
Alongside its results, Radnostix disclosed an agreement to sell assets related to a planned depleted uranium conversion and fluorine extraction facility in New Mexico to Nano Nuclear Energy and its subsidiary HALEU Energy Fuel. Consideration at closing comprises $9.5 million in cash, less escrow funds and any amounts paid to release liens on the assets, plus restricted Nano shares valued at $4 million. This is not yet a completed realization of value; closing depends on meeting conditions and obtaining approvals, including transfer of the nuclear license, site arrangements and environmental assessments. Radnostix's disclosure describes the license as a 40-year operating permit and the first of its commercial kind issued by the commission in the United States. Nano said the parties expect to complete the transaction in about 90 to 120 days from its September 28 announcement, with timing subject to approvals and conditions.
On steps related to its Sodium Iodide I-131 product, the company said sales volumes had fully recovered from July 2026 and exceeded pre-recall levels. It added that both product recalls had been fully implemented, but were still awaiting formal closure by the U.S. Food and Drug Administration. In October, Radnostix submitted a Type II drug master file to the agency for the active pharmaceutical ingredient, containing confidential manufacturing and regulatory control information that authorized parties can reference in their applications. Also in October, the company entered into a $1.0 million revolving credit facility with Bank of Commerce for 12 months at the prime rate, providing working capital and additional liquidity. The company also said it had secured supplies of gadolinium-153 and shipped commercial batches of calibration and reference products using the isotope in November, following a global disruption that lasted several years.